Literature DB >> 20127520

Complement factor H Y402H gene polymorphism and coronary heart disease susceptibility: a meta-analysis.

Hai-Feng Zhang1, Jing-Feng Wang, Yan Wang, Li-Guang Zhu, Lei Lei.   

Abstract

The complement factor H (CFH) Y402H (T1277C) gene polymorphism has been reported to be associated with coronary heart disease (CHD), but results were conflicting. To evaluate the role of the variant in CHD, we performed meta-analyses of all available data. Both electronic and manual searches were performed, all relevant studies were identified. ORs with 95% confidential intervals (CI) under codominant (CC versus TT, TC versus TT), dominant (CC + TC versus TT) and recessive (CC versus TT + TC) models were calculated. Publication bias was addressed. Ten studies including 11 cohorts comprising of 29,764 participants were included. No association between the CFH T1227C polymorphism and CHD could be found. (For overall analysis: dominant model, OR = 1.04, 95%CI: 0.97-1.11; recessive model, OR = 1.04, 95%CI: 0.97-1.11; for Caucasian subgroup: OR = 1.08 95%CI: 0.92-1.27; recessive model, OR = 1.03, 95%CI: 0.96-1.11). Two studies reported positive results in separate population (Caucasian study: recessive model, OR = 0.51, 95%CI: 0.30-0.86; Asians study: dominant model, OR = 2.37, 95%CI: 1.13-4.96). Current evidence do not support the association between the CFH T1277C polymorphism and CHD risk among common population. The association, which could be influenced by CHD onset age, CHD risk factors status and genetics backgrounds, might be significant in some population. More studies on different CHD onset ages and risk factor status should be encouraged.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20127520     DOI: 10.1007/s11033-010-9956-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  31 in total

1.  Complement factor H polymorphism in age-related macular degeneration.

Authors:  Robert J Klein; Caroline Zeiss; Emily Y Chew; Jen-Yue Tsai; Richard S Sackler; Chad Haynes; Alice K Henning; John Paul SanGiovanni; Shrikant M Mane; Susan T Mayne; Michael B Bracken; Frederick L Ferris; Jurg Ott; Colin Barnstable; Josephine Hoh
Journal:  Science       Date:  2005-03-10       Impact factor: 47.728

2.  Complement factor H Y402H gene polymorphism in coronary artery disease and atherosclerosis.

Authors:  S V Goverdhan; A J Lotery; A J Cree; S Ye
Journal:  Atherosclerosis       Date:  2006-05-30       Impact factor: 5.162

3.  CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration.

Authors:  Mingyao Li; Pelin Atmaca-Sonmez; Mohammad Othman; Kari E H Branham; Ritu Khanna; Michael S Wade; Yun Li; Liming Liang; Sepideh Zareparsi; Anand Swaroop; Gonçalo R Abecasis
Journal:  Nat Genet       Date:  2006-08-27       Impact factor: 38.330

4.  Complement factor H Y402H gene polymorphism, C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: a nested case-control study.

Authors:  Robert Y L Zee; Kirsti A Diehl; Paul M Ridker
Journal:  Atherosclerosis       Date:  2005-10-17       Impact factor: 5.162

Review 5.  Genetic and genomic insights into the molecular basis of atherosclerosis.

Authors:  Yaoyu Chen; Jarod Rollins; Beverly Paigen; Xiaosong Wang
Journal:  Cell Metab       Date:  2007-09       Impact factor: 27.287

6.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

Authors:  Donald Lloyd-Jones; Robert Adams; Mercedes Carnethon; Giovanni De Simone; T Bruce Ferguson; Katherine Flegal; Earl Ford; Karen Furie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary McDermott; James Meigs; Dariush Mozaffarian; Graham Nichol; Christopher O'Donnell; Veronique Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Randall Stafford; Julia Steinberger; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan Wong; Judith Wylie-Rosett; Yuling Hong
Journal:  Circulation       Date:  2008-12-15       Impact factor: 29.690

7.  The common Y402H variant in complement factor H gene is not associated with susceptibility to myocardial infarction and its related risk factors.

Authors:  Klaus Stark; Katharina Neureuther; Kamil Sedlacek; Wibke Hengstenberg; Marcus Fischer; Andrea Baessler; Silke Wiedmann; Andreas Jeron; Stephan Holmer; Jeanette Erdmann; Heribert Schunkert; Christian Hengstenberg
Journal:  Clin Sci (Lond)       Date:  2007-08       Impact factor: 6.124

8.  Complement factor H gene polymorphism and risk of cardiovascular disease in end-stage renal disease patients.

Authors:  Monika Buraczynska; Piotr Ksiazek; Pawel Zukowski; Ewa Benedyk-Lorens; Grazyna Orlowska-Kowalik
Journal:  Clin Immunol       Date:  2009-05-09       Impact factor: 3.969

9.  ATG16L1 T300A polymorphism and Crohn's disease susceptibility: evidence from 13,022 cases and 17,532 controls.

Authors:  Hai-Feng Zhang; Li-Xin Qiu; Yu Chen; Wa-Li Zhu; Chen Mao; Li-Guang Zhu; Ming-Hua Zheng; Yan Wang; Lei Lei; Jian Shi
Journal:  Hum Genet       Date:  2009-04-01       Impact factor: 4.132

10.  Genetic variants of complement factor H gene are not associated with premature coronary heart disease: a family-based study in the Irish population.

Authors:  Weihua Meng; Anne Hughes; Chris C Patterson; Christine Belton; Muhammad S Kamaruddin; Paul G Horan; Frank Kee; Pascal P McKeown
Journal:  BMC Med Genet       Date:  2007-09-18       Impact factor: 2.103

View more
  2 in total

1.  Association between KCNJ11 gene polymorphisms and risk of type 2 diabetes mellitus in East Asian populations: a meta-analysis in 42,573 individuals.

Authors:  Lijuan Yang; Xianghai Zhou; Yingying Luo; Xiuqin Sun; Yong Tang; Wulan Guo; Xueyao Han; Linong Ji
Journal:  Mol Biol Rep       Date:  2011-05-15       Impact factor: 2.316

2.  Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro.

Authors:  Barry W Neun; Yechezkel Barenholz; Janos Szebeni; Marina A Dobrovolskaia
Journal:  Molecules       Date:  2018-07-12       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.